Alten enjoyed high organic growth in Q2 2022, despite challenging comps. Revenue growth was 18.9% yoy at cc/cs. The performance was strong given that Q1 2021 revenues were up +19.7%. This is the fifth consecutive quarter of ~20% organic growth.
Alten Finishes 2021 with an Indian-like Growth Rate
lten finished 2021 with an India-growth rate. For the third consecutive quarter, Alten has an organic (cc/cs) revenue growth close to 20%, reaching 23.2% in Q4. The company benefitted from favorable comps (-17.4% in Q4 2020) and HR decisions.
SII Achieves Its Highest Profits Ever
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org
Alten, the Largest and Fastest-Growing in Q3!
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org
Will Alten Be A Significant Clinical Trials CRO?
ER&D services largest pure-play, Alten, has ambitions as a clinical trials contract research organization (CRO). During Q2 2021, the company completed the acquisition of Cmed. Cmed, a clinical trial CRO based in the UK. It is a small firm with EUR 20m in revenues and 180 consultants. It has specialized in oncology, immuno-oncology, cell therapy, and rare disease.
Alten: A Big Rebound in Q2
Alten impressed investors with its Q2 rebound: revenues had a big rebound (+19.7% yoy at cc/cs) to EUR 714m. We had anticipated this solid rebound: the comps were very favorable (Q2 2020 was down 18.4% yoy organically).
Alten: Toward A Growth Acceleration in Q2!
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org.
Alten Makes its Largest Acquisition Ever, in Digital
Alten is to make its largest acquisition, with Milan-headquartered SDG Group. SDG has revenues of EUR 76m and a headcount of 950. Its operating margin is ~10%. We estimate the price paid by Alten to ~EUR 60m.
Sweco, Nordics’ Alten, Impressed in Q3!
The more we get to know Sweco, the more we think it is similar to Alten. Sweco impressed in Q3 2020 by limiting its revenue decline by 2% yoy at cc/cs, to SEK 4,547m (~USD 526m).
Europe Has Entered its Second Lockdown. A Look at Financial Implications
Europe has now entered its second lockdown. The lockdowns have different restrictions levels and different lengths. The UK and France are running for the full month of November. Officials in the two countries have, however, warned the lockdown might last longer, until Christmas at least.
Alten Does Better than Expected in Q2. H2 Outlook Is Uncertain
Alten announced better than expected revenues in Q2 with a CC/CS decline of 18.4% (we expected -23%), after a growth of 4.0% in Q1. During H1, the decline was 7.3% (guidance: -9%).
Earnings Preview: Revenues of Alten to Plunge in Q2
ER&D’s largest pure-play globally, Alten, will be announcing its Q2 2020 revenue by the end of July. The company had a very decent Q1, with a 4% CC/CS revenue growth. However, it warned that revenues would be down by ~22% in Q2.
Alten Slows Down in Q4. Points to Market Adjustment
Alten’s revenues in Q4 slowed down to a growth of +7.3% yoy (at CC/CS ), following double-digit CC/CS growth during Q1-Q3 2019. The company suffered from a demanding comparison basis (+13.7% in Q4 2018), and one lesser working day in several countries (a 0.15% impact on the group’s revenues).
Alten Points to Slowing Market in 2020 Despite Good Performance in Q3 2019
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org.
Alten accelerates its effort on Industry 4.0
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org
2018: A Year in Review
2018 was an eventful year: the top ER&D vendors accelerated their M&A activities. Alten continued to deploy its business model. HCL Tech’s ERS unit had a superb year